28 January 2025
Eden Research
plc
("Eden"
or "the Company")
Director/PDMR
Shareholdings
Eden Research plc (AIM: EDEN), a
leader in sustainable biopesticide and biocontrol technology,
announces that on 28 January 2025, the following directors of Eden
purchased ordinary shares of £0.01 each in the Company ("Ordinary
Shares") at a volume-weighted average price of 3.68 pence per
Ordinary Share, as follows:
|
Director
|
Position
|
No.
of Ordinary Shares
purchased
|
|
Sean Smith
|
Chief Executive Officer
|
540,540
|
|
Alex Abrey
|
Chief Financial Officer
|
540,540
|
|
Derek McAllan
|
Non-Executive Director
|
279,022
|
Following the purchase of Ordinary
Shares detailed above, the Directors' interests in the Ordinary
Share capital of the Company are as follows:
|
Director
|
No.
of Ordinary Shares held
|
%
of issued share capital
|
|
Sean Smith
|
1,913,117
|
0.36%
|
|
Alex Abrey
|
2,314,732
|
0.43%
|
|
Derek McAllan
|
602,039
|
0.11%
|
The notifications below, made in
accordance with the requirements of the EU Market Abuse Regulation,
provide further detail.
The Directors' purchases formed part
of a wider block trade over c.5.2m Ordinary Shares in total which
fully exited a selling shareholder.
For further information
contact:
|
Eden
Research plc
|
|
|
Sean Smith
Alex Abrey
|
www.edenresearch.com
01285 359
555
|
|
Cavendish Capital Markets Limited (Nominated advisor and
broker)
|
|
|
Giles Balleny / George
Lawson (corporate finance)
Charlie Combe (corporate broking)
Michael Johnson (sales)
|
020 7220
0500
|
|
Hawthorn Advisors (Financial PR)
|
|
|
Victoria Ainsworth
|
eden@hawthornadvisors.com
|
Notes to Editors:
Eden Research is the
only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative
biopesticide products and natural microencapsulation technologies
to the global crop protection, animal health and consumer products
industries.
Eden's products are formulated with
terpene active ingredients, based on natural plant defence
metabolites. To date, they have been primarily used on high-value
fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional
pesticides. Eden has three products currently on the
market:
Based on plant-derived active
ingredients, Mevalone® is a foliar biofungicide
which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned
with the requirements of integrated pest management
programmes. It is approved for sale in a
number of key countries whilst Eden and its partners pursue
regulatory clearance in new territories thereby growing Eden's
addressable market globally.
NovellusÒ+ is an evolution of Mevalone, allowing improved rates in the
field, high levels of efficacy and a broader list of
targets.
Cedroz™ is a bionematicide that
targets free living nematodes which are parasitic worms that affect
a wide range of high-value fruit and vegetable crops
globally. Cedroz is registered for sale on two continents and
Eden's commercial collaborator, Eastman Chemical, is pursuing
registration and commercialisation of this important new product in
numerous countries globally.
Eden's seed treatment product,
Ecovelex™ was developed to
safely tackle crop destruction caused by birds - a major cause of
losses in maize and other crops. Ecovelex
works by creating an unpleasant taste or odour that repels birds,
leaving the seeds safely intact and the birds unaffected and free
to find alternative food sources. The
product is based on Eden's plant-derived chemistry, registered in
the EU, U.S. and elsewhere, and formulated using Eden's
Sustaine® microencapsulation
system.
Eden's Sustaine® encapsulation technology
is used to harness the biocidal efficacy of naturally occurring
chemicals produced by plants (terpenes) and can also be used with
both natural and synthetic compounds to enhance their performance
and ease-of-use. Sustaine microcapsules are naturally-derived,
plastic-free, biodegradable micro-spheres derived from yeast. It is
one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.
Eden was admitted to trading on AIM
on 11 May 2012 and trades under the symbol EDEN. It was
awarded the London Stock Exchange Green Economy Mark in January
2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services
that contribute to the global green economy. Eden derives 100% of
its total annual revenues from sustainable products and
services.
For more information about Eden,
please visit: www.edenresearch.com.
You can also follow Eden's latest developments via its social media
channels: X (Twitter)
and LinkedIn.
The
Company makes the following disclosures in accordance with article
19(3) of the Market Abuse Regulation:
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Alex Abrey
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Eden Research plc
|
|
b)
|
LEI
|
213800ZWTYTVQQSM3J85
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence
each
GB0001646941
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
540,540 Ordinary Shares at
3.70 pence per Ordinary Share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
28 January 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Derek McAllan
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Eden Research plc
|
|
b)
|
LEI
|
213800ZWTYTVQQSM3J85
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence
each
GB0001646941
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
279,022 Ordinary Shares at
3.58 pence per Ordinary Share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
28 January 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Sean Smith
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Eden Research plc
|
|
b)
|
LEI
|
213800ZWTYTVQQSM3J85
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1 pence
each
GB0001646941
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
540,540 Ordinary Shares at
3.70 pence per Ordinary Share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
28 January 2025
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
